PrEP HIV-prevention clinic opens at Duke
Treatment Terms
Infectious diseases
Additional SEO Keywords
HIV prevention, PrEP HIV, HIV PrEP, What is PrEP, Truvada, Truvada PrEP, pre-exposure prophylaxis
SEO Meta Description
Duke PrEP clinic helps people at high risk for HIV take steps to prevent infection. Read answers to your questions about HIV PrEP.
Author
MaryAnn Fletcher
Overview
Duke's new <a href="/locations/duke-prep-clinic-hiv-prevention">PrEP clinic</a> helps people at high risk for HIV take steps to prevent infection. Read answers to your questi...
Source: dukehealth.org: Health Features - July 14, 2016 Category: Universities & Medical Training Authors: mf205 at duke.edu Source Type: news
Advocates for HIV prevention pill push for better access, information
The drug Truvada has been used to treat HIV for over a decade and recent clinical trials show, if taken daily, it can also reduce the risk of getting HIV by more than 90 per cent. But doctors aren't yet familiar with the drug and it can cost up to $1,000 a month. (Source: CBC | Health)
Source: CBC | Health - July 11, 2016 Category: Consumer Health News Tags: News/Canada/Nova Scotia Source Type: news
Here's Why Anti-HIV Drugs May Not Be Reaching Those Most At Risk
Only a small proportion of gay and bisexual men who could have taken a daily pill to reduce their risk of HIV actually did so in 2014, according to a new study.
Furthermore, young gay and bisexual men and those of color, who are among the groups most at risk for infection with the human immunodeficiency virus (HIV), were less likely to be taking the medication than their older and white counterparts.
Unequal use of the drug, called Truvada, may worsen the disparities between races in HIV rates, said lead author Henry Raymond, of the San Francisco Department of Public Health.
“We don’t want to leave anyone behin...
Source: Healthy Living - The Huffington Post - July 8, 2016 Category: Consumer Health News Source Type: news
11 new AMA policies patients should know
At the heart of all policymaking of the AMA is the mission to promote the betterment of public health. Physicians at the 2016 AMA Annual Meeting adopted a variety of policies that will help improve consumer safety and reduce harm—they range from preventing drug overdose to delaying school start times and supporting paid sick leave.
1. Medication disposal programs could help prevent overdose, improve health
An unprecedented drug overdose epidemic in the United State could be addressed in part by stronger medication return programs that treat unused medications as hazardous waste. The AMA called for support of medicati...
Source: AMA Wire - June 15, 2016 Category: Journals (General) Authors: Amy Farouk Source Type: news
New AMA policies patients should know
At the heart of all policymaking of the AMA is the mission to promote the betterment of public health. Physicians at the 2016 AMA Annual Meeting adopted a variety of policies that will help improve consumer safety and reduce harm.
Dangers of detergent packets
Recognizing that concentrated detergent packets can compromise children’s health and safety, the AMA today adopted policy calling for the redesign of detergent product packages to make them less attractive to children to help prevent accidental exposure or ingestion.
According to a study published in the Journal of the American Academy of Pediatrics, between 2...
Source: AMA Wire - June 14, 2016 Category: Journals (General) Authors: Amy Farouk Source Type: news
Topical application of antiretroviral drug combination prevents transmission of (S)HIV
For the first time, researchers show that two powerful antiretroviral drugs can provide complete protection against HIV when delivered topically by a sustained release intravaginal ring (IVR) device. The combination of tenofovir disoproxil fumarate and emtricitabine delivered at independently controlled rates via the pod-IVR was successful at preventing SHIV162p3 infection for over four months. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 13, 2016 Category: Science Source Type: news
Topical application of antiretroviral drug combination prevents transmission of (S)HIV
(Oak Crest Institute of Science) Findings published last week in the journal PLOS ONE confirm that researchers from the Oak Crest Institute of Science have demonstrated for the first time that two powerful antiretroviral drugs can provide complete protection against HIV when delivered topically by a sustained release intravaginal ring (IVR) device. The combination of tenofovir disoproxil fumarate and emtricitabine delivered at independently controlled rates via the pod-IVR was successful at preventing SHIV162p3 infection for over four months. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 13, 2016 Category: Global & Universal Source Type: news
TAF vs TDF for Initial HIV-1 TreatmentTAF vs TDF for Initial HIV-1 Treatment
When compared to tenofovir disoproxil fumarate, is tenofovir alafenamide with elvitegravir, cobicistat, and emtricitabine a safe and durable regimen for initial HIV treatment? JAIDS: Journal of Acquired Immune Deficiency Syndromes (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - June 8, 2016 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news
Can an anti-HIV drug break down wall between HIV-positive and HIV-negative men?
Health Canada and researchers say HIV-prevention drug Truvada is another line of defence to be used along with condoms, but preliminary results from a two-year study show condomless sex between HIV-positive men and HIV-negative men taking the drug increased among the study's 52 participants. (Source: CBC | Health)
Source: CBC | Health - June 2, 2016 Category: Consumer Health News Tags: News/Health Source Type: news
Descovy (Emtricitabine and Tenofovir Alafenamide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 18, 2016 Category: Drugs & Pharmacology Source Type: news
Descovy (emtricitabine, tenofovir alafenamide) for the Treatment of HIV-1 Infection
Descovy (emtricitabine200mg/tenofovir alafenamide25mg, F/TAF) is developed by Gilead sciences for the treatment of HIV-1 infection in adults and children above 12 years of age. (Source: Drug Development Technology)
Source: Drug Development Technology - May 5, 2016 Category: Pharmaceuticals Source Type: news
CHMP Likes Gilead's TAF-Based HIV Regimen OdefseyCHMP Likes Gilead's TAF-Based HIV Regimen Odefsey
Odefsey is a fixed-dose combination pill containing emtricitabine, rilpivirine, and tenofovir alafenamide that recently cleared the US Food and Drug Administration. International Approvals (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - April 29, 2016 Category: Infectious Diseases Tags: HIV/AIDS News Alert Source Type: news
EC grants marketing authorisation for Gilead Sciences’ Descovy F/TAF
The European Commission (EC) has granted marketing authorisation to biopharmaceutical company Gilead Sciences, for two doses of Descovy (emtricitabine and tenofovir alafenamide 200/10mg and 200/25mg; F/TAF). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 26, 2016 Category: Pharmaceuticals Source Type: news
Gay Men Follow HIV Prevention Regimen, if MDs Prescribe ItGay Men Follow HIV Prevention Regimen, if MDs Prescribe It
Gay and bisexual men who take a Truvada pill daily to prevent HIV infection did better than researchers expected at sticking to their medication schedule, according to a new report. Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - April 7, 2016 Category: Infectious Diseases Tags: Family Medicine/Primary Care News Source Type: news
FDA Okays Third, Gentler Form of Tenofovir for HIV (Descovy)FDA Okays Third, Gentler Form of Tenofovir for HIV (Descovy)
The new drug is identical to Truvada except that tenofovir alafenamide replaces tenofovir disoproxil fumarate. FDA Approvals (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - April 5, 2016 Category: Infectious Diseases Tags: HIV/AIDS News Alert Source Type: news
